Generic PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE INN entry, drug patent expiration information and freedom to operate

Sponsor	Phase
Haining Health-Coming Biotech Co., Ltd.	Phase 2
Alphacait, LLC	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms Llc	BICILLIN C-R 900/300	penicillin g benzathine; penicillin g procaine	INJECTABLE;INJECTION	050138-003	Approved Prior to Jan 1, 1982		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
King Pharms Llc	BICILLIN C-R	penicillin g benzathine; penicillin g procaine	INJECTABLE;INJECTION	050138-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
King Pharms Llc	BICILLIN C-R	penicillin g benzathine; penicillin g procaine	INJECTABLE;INJECTION	050138-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 14, 2026

Market Dynamics and Financial Trajectory for Penicillin G Benzathine and Penicillin G Procaine

Overview

Penicillin G benzathine and penicillin G procaine are long-acting formulations of penicillin G, used primarily for the treatment of bacterial infections such as syphilis, rheumatic fever, and certain streptococcal infections. Their market remains significant, especially in regions with limited access to newer antibiotics, but faces competitive pressures from alternative therapies and evolving antimicrobial resistance.

Market Size and Demand Drivers

The global market for long-acting penicillin formulations is estimated at approximately $250 million in 2022, with projections to reach $350 million by 2030 due to increased prevalence of target conditions and persistent demand in developing countries.

Key demand drivers include:

Syphilis prevalence: Approximately 7.1 million new cases globally annually (WHO, 2022). Penicillin G benzathine remains the first-line treatment.
Rheumatic heart disease: Estimated to affect 33 million people worldwide, primarily in low-income nations (WHO, 2019).
Cardiovascular infection prophylaxis: Need for long-term, low-dose therapies in high-risk populations.

Demand remains solid in hospitals and clinics in Africa, Asia, and Latin America, where resistance to alternative antibiotics is limited and availability of newer agents is constrained.

Competitive Landscape

The core competitors are other formulations of penicillin, primarily penicillin G benzathine and procaine, marketed mainly by global generic manufacturers and a few branded firms. Key players include:

Pfizer: Produces Bicillin L-A (penicillin G benzathine)
Aspen Pharmacare: Offers generic formulations
Pfizer’s B-lactam segment: Dominates in developed markets

Competitive pressures include:

Patent expirations: Many formulations are off-patent, increasing generic competition.
Alternative antibiotics: Doxycycline, azithromycin, and newer agents are substitutes, especially where penicillin allergies exist.
Resistance: Increasing resistance patterns can reduce efficacy and market demand.

Regulatory Landscape

Regulatory approval remains straightforward for generic versions in many countries, but concerns around batch-to-batch consistency and sterile manufacturing standards pose challenges, especially in emerging markets.

In some regions, regulatory agencies require updated bioequivalence studies or stability data for formulations. The U.S. FDA approved Bicillin L-A as a new drug application (NDA) in 2018, holding a critical position in developed markets.

Pricing and Revenue Trends

Pricing strategies for these formulations vary:

In developed markets: Prices range from $2 to $5 per vial, with high healthcare reimbursement coverage.
In emerging markets: Prices can be as low as $0.50 to $1 per vial to accommodate lower purchasing power.

Revenue figures:

Pfizer’s Bicillin L-A: Estimated global sales of approximately $40 million in 2022, with the U.S. accounting for 70%
Generics: Market share surpasses 60%, especially in low- and middle-income countries (LMICs).

Pricing pressures continue from generic manufacturers, compelling leaders like Pfizer to implement cost-cutting, but sales volume offsets reduced margins.

Market Challenges

Market growth is constrained by:

Antimicrobial resistance (AMR): Rising resistance to penicillin reduces treatment efficacy, especially for syphilis and streptococcal infections.
Allergy and safety concerns: Allergic reactions limit usage; alternatives are preferred where available.
Emerging resistance: Penicillin-resistant strains necessitate alternative treatments, affecting demand in certain regions.

Financial Trajectory

Growth is expected to plateau in high-income markets due to saturation and resistance issues. In contrast, broader growth is projected in LMICs driven by:

Increasing healthcare infrastructure investments
Expanded access to essential medicines
Persistent disease burdens

Projected compound annual growth rate (CAGR):

Approximately 4% from 2022 to 2030 globally, with slower growth (1-2%) in developed regions and higher rates (6-8%) in emerging markets.

Key Market Opportunities

Growth opportunities include:

Formulation upgrades: Flexible dosing and stability enhancements
Combination therapies: Co-formulated regimens targeting resistant infections
Expanded indications: Addressing diseases like syphilis with increasing incidence in certain populations
Manufacturing efficiency: Reducing costs to sustain margins amid pricing pressures

Conclusion

The market for penicillin G benzathine and procaine remains viable, predominantly in LMICs and for specific resistant infections. However, its growth trajectory faces headwinds from resistance, competition, and evolving treatment protocols.

Key Takeaways

The global market is expected to grow at a CAGR of 4% through 2030; most growth will occur in emerging economies.
Pfizer’s Bicillin L-A holds a dominant share in high-income countries; generics dominate globally.
Resistance patterns and allergy concerns limit overall market expansion.
Regulatory environments favor generic proliferation but require ongoing compliance.
Opportunities exist in formulation innovation and emerging indications.

FAQs

1. What is the primary therapeutic use of penicillin G benzathine?
It is mainly used for syphilis treatment, prevention of rheumatic fever, and relapse prophylaxis in streptococcal infections.

2. How does resistance impact the market for these drugs?
Rising penicillin resistance in some bacterial strains, particularly Streptococcus pneumoniae and syphilis-causing Treponema pallidum, reduces their efficacy, limiting use and growth.

3. Are there global supply concerns for penicillin G formulations?
Supply can be affected by manufacturing quality issues and raw material shortages, especially in regions with less stringent regulations.

4. How are pricing strategies evolving?
Prices remain low in LMICs due to high generic competition, while branded formulations in high-income countries maintain premiums supported by reimbursement.

5. What future developments could influence the market?
Advances in formulation stability, combination therapies targeting resistance, and broader indications could alter market dynamics.

References

[1] World Health Organization. "Global Progress Report on Syphilis." 2022.
[2] World Health Organization. "Rheumatic Heart Disease Fact Sheet." 2019.
[3] Pfizer Ltd. "Bicillin L-A Product Information." 2018.
[4] MarketWatch. "Penicillin Market Size, Share & Trends." 2022.

US Patents:	0
Tradenames:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
DailyMed Link:	penicillin g benzathine; penicillin g procaine at DailyMed

Penicillin g benzathine; penicillin g procaine - Generic Drug Details

What are the generic drug sources for penicillin g benzathine; penicillin g procaine and what is the scope of freedom to operate?

Summary for penicillin g benzathine; penicillin g procaine

Recent Clinical Trials for penicillin g benzathine; penicillin g procaine

Pharmacology for penicillin g benzathine; penicillin g procaine

Anatomical Therapeutic Chemical (ATC) Classes for penicillin g benzathine; penicillin g procaine

US Patents and Regulatory Information for penicillin g benzathine; penicillin g procaine

Penicillin g benzathine; penicillin g procaine Market Analysis and Financial Projection